Metastatic Colorectal Cancer
9 competing products in clinical development for Metastatic Colorectal Cancer.
Pipeline by Phase
Pre-clinical1
Phase 12
Phase 1/21
Phase 24
Phase 31
All Products (9)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Ipilimumab + Oxaliplatin + Leucovorin + Fluorouracil + Irinotecan + Bevacizumab + Cetuximab + Nivolumab | Ono Pharmaceutical | Phase 3 | Active | 44 |
| Enfortumab Vedotin | Astellas Pharma | Phase 2 | Recruiting | 42 |
| Tivantinib + Placebo + Cetuximab + Irinotecan | Daiichi Sankyo | Phase 1/2 | Completed | 32 |
| Bevacizumab + 5-fluorouracil + Leucovorin calcium + Irinotecan hydrochloride + Oxaliplatin + Capecitabine | Chugai Pharmaceutical | Phase 2 | UNKNOWN | 31 |
| CS-1008 + FOLFIRI | Daiichi Sankyo | Phase 1 | Completed | 29 |
| CS-1008 + irinotecan | Daiichi Sankyo | Phase 2 | Terminated | 27 |
| Patritumab Deruxtecan | Daiichi Sankyo | Phase 2 | Terminated | 27 |
| CPT-11 based regimens | Daiichi Sankyo | Pre-clinical | Completed | 26 |
| ZN-c3 + Encorafenib + Cetuximab | Zentalis Pharmaceuticals | Phase 1 | Terminated | 11 |